Entero Healthcare Solutions Valuation
Is ENTERO undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of ENTERO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate ENTERO's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate ENTERO's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ENTERO?
Key metric: As ENTERO is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is ENTERO's PE Ratio? | |
|---|---|
| PE Ratio | 81.5x |
| Earnings | ₹714.39m |
| Market Cap | ₹58.19b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.3x |
| Enterprise Value/EBITDA | 50.5x |
| PEG Ratio | 1.6x |
Price to Earnings Ratio vs Peers
How does ENTERO's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 33.5x | ||
REMUS Remus Pharmaceuticals | 46.4x | n/a | ₹13.9b |
DENTALKART Vasa Denticity | 56.5x | n/a | ₹9.9b |
BALAXI Balaxi Pharmaceuticals | 11.3x | n/a | ₹4.0b |
QMSMEDI QMS Medical Allied Services | 20x | n/a | ₹2.0b |
ENTERO Entero Healthcare Solutions | 81.5x | 49.9% | ₹58.2b |
Price-To-Earnings vs Peers: ENTERO is expensive based on its Price-To-Earnings Ratio (81.5x) compared to the peer average (33.5x).
Price to Earnings Ratio vs Industry
How does ENTERO's PE Ratio compare vs other companies in the IN Healthcare Industry?
Price-To-Earnings vs Industry: ENTERO is expensive based on its Price-To-Earnings Ratio (81.5x) compared to the Indian Healthcare industry average (41.8x).
Price to Earnings Ratio vs Fair Ratio
What is ENTERO's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 81.5x |
| Fair PE Ratio | 96.8x |
Price-To-Earnings vs Fair Ratio: ENTERO is good value based on its Price-To-Earnings Ratio (81.5x) compared to the estimated Fair Price-To-Earnings Ratio (96.8x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | ₹1,337.95 | ₹1,664.67 +24.4% | 3.4% | ₹1,724.00 | ₹1,590.00 | n/a | 3 |
| Nov ’25 | ₹1,428.90 | ₹1,509.33 +5.6% | 4.4% | ₹1,590.00 | ₹1,428.00 | n/a | 3 |
| Oct ’25 | ₹1,376.05 | ₹1,509.33 +9.7% | 4.4% | ₹1,590.00 | ₹1,428.00 | n/a | 3 |
| Sep ’25 | ₹1,368.05 | ₹1,509.33 +10.3% | 4.4% | ₹1,590.00 | ₹1,428.00 | n/a | 3 |
| Aug ’25 | ₹1,260.40 | ₹1,509.33 +19.8% | 4.4% | ₹1,590.00 | ₹1,428.00 | n/a | 3 |
| Jul ’25 | ₹1,064.10 | ₹1,509.33 +41.8% | 4.4% | ₹1,590.00 | ₹1,428.00 | n/a | 3 |
| Jun ’25 | ₹1,028.35 | ₹1,509.33 +46.8% | 4.4% | ₹1,590.00 | ₹1,428.00 | n/a | 3 |
| May ’25 | ₹1,170.70 | ₹1,511.00 +29.1% | 4.2% | ₹1,590.00 | ₹1,433.00 | n/a | 3 |
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.
Discover undervalued companies
Dr Lalchandani Labs
₹81.2m
Provides diagnostic and related healthcare tests and services in India.
541299
₹18.73
7D
4.1%
1Y
-46.5%
N G Industries
₹566.9m
Provides various healthcare services in India.
530897
₹169.20
7D
3.2%
1Y
1.3%
Adeshwar Meditex
₹340.0m
Manufactures and exports sterile wound dressings, first aid kits, pharmaceuticals, and other medical disposables in India and internationally.
543309
₹23.56
7D
0%
1Y
-5.8%